Commercial Considerations for the Development of an Antitheilerial Product

Abstract

The development of a modern anti-protozoal product from discovery to market is an increasingly difficult, expensive, but always interesting project for pharmaceutical companies and their cooperators. Regulatory authorities in the home country of the manufacturer and in the target market together with the increasingly sensitive corporate conscience have ensured the evolution of a development network of growing complexity and cost. There are additional constraints imposed on sales and distribution of the final products in some target markets which all combine to ensure a more cautious approach to development of promising discovery compounds and inevitably slower and more expensive research by fewer companies. This paper will attempt to address some of these issues.